Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/28/2026

1. NVDA
2. MIRM
3. USO
4. SHEL
5. LLY

6. ACN
7. PSKY
8. WBD
9. FCN
10. SNOW

Get Alerts ALDR Hot Sheet

Price: $18.88 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

BOTHELL, Wash., April 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview and update at the 18th Annual Needham Healthcare Conference at 10:40 am ET on Tuesday, April 9, 2019 in New York, NY.

The presentation will be webcast live on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.

Link: http://wsw.com/webcast/needham90/aldr/

About Alder BioPharmaceuticals, Inc.Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.

Investor Relations Contact: Michael SchaffzinStern Investor Relations, Inc.212.362.1200[email protected]

Media Contact: Ashley CadleTogoRun[email protected]310.463.0143